Unraveling the mechanisms of IVIG immunotherapy in MIS-C.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 34608458.
- Also identified by DOI 10.1016/j.xcrm.2021.100431 and PMC identifier 8481087.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In <i>The Journal of Clinical Investigation</i>, Zhu et al.<sup>1</sup> report that intravenous immunoglobulin (IVIG) targets IL-1β<sup>+</sup> neutrophils to exert anti-inflammatory effects in multisystem inflammatory syndrome in children (MIS-C), a post-infectious inflammatory condition associated with COVID-19.
Medical subject headings
- COVID-19
- Immunoglobulins, Intravenous